**Table S2.** Baseline characteristics, clinical course of index hospitalization and pharmacotherapy in hospitalized HFpEF patients in SR stratified by heart rate at discharge <70 and ≥70 b.p.m. (from the Polish cohort of the ESC-HF-LT registry).

|  |  |  |  |
| --- | --- | --- | --- |
|  | **HFpEF,**  **SR <70/min**  ***(n=51; 47.7*%)** | **HFpEF,**  **SR ≥70/min**  ***(n=56; 52.3*%)** | ***P*-value** |
| **Demographics** | | | |
| Age, yrs | 76.1 (65.6-79.8) | 73.9 (66.6-83.3) | 0.94 |
| Male | 24 (47.1%) | 23 (41.1%) | 0.56 |
| BMI, kg/m2 | 28.0 (25.0-32.5) | 28.5 (26.0-33.1) | 0.43 |
| **Medical history** | | | |
| Previous HF hospitalization | 23/50 (46%) | 22 (39.3%) | 0.56 |
| Ischemic etiology | 25 (49.0%) | 19 (33.9%) | 0.12 |
| Valve disease | 8 (15.7%) | 13 (23.2%) | 0.47 |
| Hypertension | 37 (72.5%) | 44 (78.6%) | 0.51 |
| Atrial fibrillation | 14 (27.5%) | 14 (25.0%) | 0.83 |
| Coronary artery disease | 24 (47.1%) | 21 (37.5%) | 0.33 |
| Prior PCI or CABG | 12 (23.5%) | 12 (21.4%) | 0.82 |
| Peripheral artery disease | 5 (9.8%) | 11 (19.6%) | 0.18 |
| Diabetes | 20 (39.2%) | 20 (35.7%) | 0.84 |
| Chronic kidney disease | 10 (19.6%) | 14 (25.0%) | 0.64 |
| COPD | 4 (7.8%) | 10 (17.9%) | 0.16 |
| Stroke | 6 (11.8%) | 4 (7.1%) | 0.51 |
| Current smoking | 17 (33.3%) | 26 (46.4%) | 0.23 |
| Alcohol\* | 25/50 (50.0%) | 30 (53.6%) | 0.85 |
| **Clinical status at admission** | | | |
| NYHA class | | | 0.21 |
| I | 0 (0%) | 0 (0%) | - |
| II | 19 (37.3%) | 12 (21.4%) | **-** |
| III | 17 (33.3%) | 24 (42.9%) | **-** |
| IV | 15 (29.4%) | 20 (35.7%) | **-** |
| Heart rate, b.p.m. | 70.0 (62.5-78.5) | 80.0 (72.0-91.2) | **<0.001** |
| SBP, mmHg | 140.0 (130.0-170.0) | 130.0 (120.0-150.0) | **0.009** |
| DBP, mmHg | 80.0 (70.0-90.0) | 80.0 (70.0-86.2) | 0.85 |
| **Laboratory findings at admission** | | | |
| Hemoglobin, g/dl | 12.9 (11.7-14.2)  *49* | 13.1 (11.4- 14.2) | 0.79 |
| Serum creatinine, mg/dl | 1.1 (0.8 to 1.4  *50* | 1.0 (0.8 to 1.2)  *55* | 0.49 |
| Serum sodium, mmol/l | 140.0 (138.0-141.9)  *50* | 140.0 (136.0-141.9)  *55* | 0.54 |
| Serum potassium, mmol/l | 4.7 (4.3-5.0)  *50* | 4.6 (4.2-4.8) | 0.19 |
| BNP, pg/ml | 191.8 (114.2-447.9)  *12* | 160.0 (110.0-322.0)  *9* | 0.94 |
| NT-proBNP, pg/ml | 993.0 (487.5-1702.0)  *15* | 2035.0 (376.0-4288.0)  *21* | 0.47 |
| **Clinical status at discharge** | | | |
| NYHA class | | | 0.59 |
| I | 4 (7.8%) | 2 (3.6%) | **-** |
| II | 35 (68.6%) | 35 (62.5%) | **-** |
| III | 11 (21.6%) | 18 (32.1%) | **-** |
| IV | 1 (2.0%) | 1 (1.8%) | **-** |
| Heart rate, b.p.m. | 61.0 (60.0- 65.0) | 75.0 (70.8-80.0) | **<0.001** |
| Change in heart rate, b.p.m.\*\* | -8.0 (-16.0 to -3.0) | -3.0 (-20.0 to 3.0) | 0.14 |
| SBP, mmHg | 130.0 (110.0-140.0) | 125.0 (110.0-132.5) | 0.64 |
| DBP, mmHg | 70.0 (70.0-80.0) | 72.5 (70.0-80.0) | 0.54 |
| **Laboratory findings at discharge** | | | |
| Hemoglobin, g/dl | 13.1 (12.1-13.8)  *30* | 13.0 (11.0-14.1)  *41* | 0.90 |
| Serum creatinine, mg/dl | 1.1 (0.9 to 1.5)  *34* | 1.0 (0.9 to 1.2)  *40* | 0.31 |
| Serum sodium, mmol/l | 139.0 (136.9-141.8)  *34* | 140.1 (137.0-142.0)  *48* | 0.49 |
| Serum potassium, mmol/l | 4.4 (4.0-4.6)  *34* | 4.4 (4.2-4.7)  *48* | 0.36 |
| **Pharmacotherapy at hospital discharge** | | | |
| Beta-blocker | 38 (74.5%) | 45 (80.4%) | 0.50 |
| Dose of beta-blocker \*\*\* | 2.5 (2.5-7.5)  *45* | 5.0 (2.5-5.0)  *51* | 0.78 |
| Digoxin | 2 (3.9%) | 5 (8.9%) | 0.44 |
| Ivabradine | 0 (0%) | 0 (0%) | 1.00 |
| Amiodaron | 5 (9.8%) | 5 (8.9%) | 1.00 |
| Other antiarrhythmics | 5 (9.8%) | 5 (8.9%) | 1.00 |
| Diuretics | 40 (78.4%) | 47 (83.9%) | 0.62 |
| ACE-I\*\*\*\* | 30 (58.8%) | 31 (55.4%) | 0.85 |
| Dose of ACE-I | 10.0 (3.1-10.0)  *30* | 5.0 (2.5 -8.8)  *30* | 0.06 |
| ARB | 9 (17.6%) | 9 (16.1%) | 1.00 |
| Aldosterone antagonist | 15 (29.4%) | 26 (46.4%) | 0.08 |
| Dose of aldosterone antagonist\*\*\*\*\* | 25.0 (25.0-50.0)  *9* | 25.0 (25.0-25.0)  *7* | 0.90 |
| CCB | 21 (41.2%) | 16 (28.6%) | 0.22 |
| Statins | 33 (64.7%) | 34 (60.7%) | 0.69 |
| Anticoagulants | 12 (23.5%) | 18 (32.1%) | 0.39 |
| Antiplatelets | 38 (74.5%) | 31 (55.4%) | **0.045** |

ACE-I - angiotensin-converting-enzyme inhibitor, ARB - angiotensin receptor blocker, BNP - B-type natriuretic peptide, BMI - body mass index, b. p. m. - beats per minute, CABG - coronary artery bypass grafting, CCB – calcium channel blocker, COPD - chronic obstructive pulmonary disease, DBP – diastolic blood pressure, ESC-HF-LT - European Society of Cardiology Heart Failure Long-Term Registry, HF - heart failure, HFpEF – heart failure with persistent ejection fraction, NT-proBNP - N-terminal-pro- B-type natriuretic peptide, NYHA – New York Heart Association, PCI - percutaneous coronary intervention, SBP - systolic blood pressure, SR – sinus rhythm, yrs – years

Red bolded text indicates *p-*values <0.05.

Numbers in italics indicate available cases for the analyzed continuous variable.

\* former or sometimes

\*\* change was calculated as the heart rate on admission minus the heart rate at discharge

\*\*\* total daily doses of commonly used beta-blockers converted to the corresponding dose of bisoprolol

\*\*\*\* total daily doses of commonly used ACE-Is converted to the corresponding dose of ramipril

\*\*\*\*\* total daily doses of commonly used aldosterone antagonists converted to the corresponding dose of eplerenone